ArticleJournal of advanced research2026
Adaptation of plateau frog peptide: From antimicrobial to angiogenic and proliferative functions.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAmphibian skin peptides, particularly defensins, play important roles in environmental adaptation, but often exhibit functional redundancy. SC17-2, a novel peptide from the high altitude frog Nanorana parkeri, exhibits unique angiogenesis and cell migration promoting activities, allowing adaptation to the extreme environment of the Tibetan Plateau with high UV radiation and low microbial diversity.
objectivesThis study aimed to investigate the adaptive role of SC17-2 in high-UV environments, its functional differences from typical defensins, and its potential biomedical applications in wound healing and angiogenesis.
methodsBioinformatics analyses, including sequence alignment and ancestral reconstruction, identified positively selected amino acid sites in SC17-2. Molecular docking examined its interaction with the epidermal growth factor receptor (EGFR). In vitro and in vivo experiments, using mouse and zebrafish models, assessed its wound healing and angiogenic properties.
resultsSC17-2 exhibited no antimicrobial activity, but it demonstrated antioxidant activity and potent wound healing and angiogenic properties. Molecular docking indicated that SC17-2 interacts with EGFR, potentially activating downstream signalling pathways. In vivo experiments showed that SC17-2 significantly accelerated wound healing by promoting collagen regeneration and angiogenesis, in some aspects outperforming VEGF.
conclusionSC17-2 represents a unique functional divergence in amphibian peptides, driven by ecological adaptation rather than microbial pressure. Its ability to promote angiogenesis and cell migration highlights its potential as a novel therapeutic agent for regenerative medicine, shaped by the extreme conditions of the Tibetan Plateau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.